Nanomedicine for respiratory diseases
Identifieur interne : 001847 ( Main/Exploration ); précédent : 001846; suivant : 001848Nanomedicine for respiratory diseases
Auteurs : Hulda Swai [Afrique du Sud] ; Boitumelo Semete [Afrique du Sud] ; Lonji Kalombo [Afrique du Sud] ; Paul Chelule [Afrique du Sud] ; Kevin Kisich [États-Unis] ; Bob Sievers [États-Unis]Source :
- Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology [ 1939-5116 ] ; 2009-05.
English descriptors
- Teeft :
- Airway, Airway epithelium, Allergic, Allergic asthma, Allergic rhinitis, Allergy clin immunol, Antibiotic, Asthma, Biol chem, Brosis, Cationic polymers, Cellular uptake, Chitosan, Chitosan nanospheres, Chloride ions, Control release, Current drug delivery approaches, Cystic, Drug deliv, Drug delivery, Epithelium, Gene, Gene delivery, Gene therapy, Gene transfer, Genet vaccines, High doses, Infection, Kumar, Lung function, Magnetic particles, Mild asthma, Mouse model, Nanobiotechnology nanomedicine, Nanomedicine, Nanoparticles, Nanoparticulate, Nanoparticulate delivery systems, Nanospheres, Nasal epithelium, Other hand, Polymer, Polymeric material, Promising approach, Pulmonary delivery, Respir, Respir crit care, Respiratory diseases, Respiratory infections, Respiratory syncytial virus infection, Side effects, Syncytial virus, Theophylline, Thiolated chitosan nanoparticles, Tissue engineering, Toxic effects, Tract infections, Transfection, Vaccine, Wires nanomedicine, World health organization.
Abstract
Treatment of respiratory diseases and infections has proved to be a challenging task, with the incidence of these ailments increasing worldwide. Nanotechnology‐based drug and gene delivery systems offer a possible solution to some of the shortfalls of the current treatment regimen. Nanobased drug delivery systems have revolutionised the field of pharmacotherapy by presenting the ability to alter the pharmacokinetics of the conventional drugs to extend the drug retention time, reduce the toxicity and increase the half‐life of the drugs. Delivery of exogenous genes to the airway epithelium in vivo has been limited by several physiological barriers, resulting in the low success rate of these systems. With the advent of nanotechnology, DNA compacted with cationic polymers to produce nanoparticles has exhibited a significant increase in the transfection efficiencies. With nanoparticulate drug/gene delivery systems, specific cells can be targeted by functionalising the polymeric nanoparticles with ligands that allow the particles to dock at a specific site of the cell. In addition, polymeric systems allow for the cargo to be released in a controlled and stimuli‐responsive manner. The advantages that nanoparticulate delivery systems present in the treatment of respiratory diseases and infections are summarised in this review. Copyright © 2009 John Wiley & Sons, Inc. For further resources related to this article, please visit the WIREs website.
Url:
DOI: 10.1002/wnan.33
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002446
- to stream Istex, to step Curation: 002446
- to stream Istex, to step Checkpoint: 000772
- to stream Main, to step Merge: 001851
- to stream Main, to step Curation: 001847
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nanomedicine for respiratory diseases</title><author><name sortKey="Swai, Hulda" sort="Swai, Hulda" uniqKey="Swai H" first="Hulda" last="Swai">Hulda Swai</name></author><author><name sortKey="Semete, Boitumelo" sort="Semete, Boitumelo" uniqKey="Semete B" first="Boitumelo" last="Semete">Boitumelo Semete</name></author><author><name sortKey="Kalombo, Lonji" sort="Kalombo, Lonji" uniqKey="Kalombo L" first="Lonji" last="Kalombo">Lonji Kalombo</name></author><author><name sortKey="Chelule, Paul" sort="Chelule, Paul" uniqKey="Chelule P" first="Paul" last="Chelule">Paul Chelule</name></author><author><name sortKey="Kisich, Kevin" sort="Kisich, Kevin" uniqKey="Kisich K" first="Kevin" last="Kisich">Kevin Kisich</name></author><author><name sortKey="Sievers, Bob" sort="Sievers, Bob" uniqKey="Sievers B" first="Bob" last="Sievers">Bob Sievers</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4644A806C6CEE0618457F71979419A298BD69F69</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/wnan.33</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-S30QXKHK-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002446</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002446</idno><idno type="wicri:Area/Istex/Curation">002446</idno><idno type="wicri:Area/Istex/Checkpoint">000772</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000772</idno><idno type="wicri:doubleKey">1939-5116:2009:Swai H:nanomedicine:for:respiratory</idno><idno type="wicri:Area/Main/Merge">001851</idno><idno type="wicri:Area/Main/Curation">001847</idno><idno type="wicri:Area/Main/Exploration">001847</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Nanomedicine for respiratory diseases</title><author><name sortKey="Swai, Hulda" sort="Swai, Hulda" uniqKey="Swai H" first="Hulda" last="Swai">Hulda Swai</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Council for Scientific and Industrial Research Polymers & Bioceramics, Pretoria, 0001</wicri:regionArea><wicri:noRegion>0001</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Afrique du Sud</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Correspondence address: Council for Scientific and Industrial Research Polymers & Bioceramics, Pretoria, 0001</wicri:regionArea><wicri:noRegion>0001</wicri:noRegion></affiliation></author><author><name sortKey="Semete, Boitumelo" sort="Semete, Boitumelo" uniqKey="Semete B" first="Boitumelo" last="Semete">Boitumelo Semete</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Council for Scientific and Industrial Research Polymers & Bioceramics, Pretoria, 0001</wicri:regionArea><wicri:noRegion>0001</wicri:noRegion></affiliation></author><author><name sortKey="Kalombo, Lonji" sort="Kalombo, Lonji" uniqKey="Kalombo L" first="Lonji" last="Kalombo">Lonji Kalombo</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Council for Scientific and Industrial Research Polymers & Bioceramics, Pretoria, 0001</wicri:regionArea><wicri:noRegion>0001</wicri:noRegion></affiliation></author><author><name sortKey="Chelule, Paul" sort="Chelule, Paul" uniqKey="Chelule P" first="Paul" last="Chelule">Paul Chelule</name><affiliation wicri:level="1"><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Council for Scientific and Industrial Research Polymers & Bioceramics, Pretoria, 0001</wicri:regionArea><wicri:noRegion>0001</wicri:noRegion></affiliation></author><author><name sortKey="Kisich, Kevin" sort="Kisich, Kevin" uniqKey="Kisich K" first="Kevin" last="Kisich">Kevin Kisich</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Jewish Medical and Research Center, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Sievers, Bob" sort="Sievers, Bob" uniqKey="Sievers B" first="Bob" last="Sievers">Bob Sievers</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>AKIN‐DRYLLC, Boulder, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</title><title level="j" type="alt">WILEY INTERDISCIPLINARY REVIEWS: NANOMEDICINE AND NANOBIOTECHNOLOGY</title><idno type="ISSN">1939-5116</idno><idno type="eISSN">1939-0041</idno><imprint><biblScope unit="vol">1</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="255">255</biblScope><biblScope unit="page" to="263">263</biblScope><biblScope unit="page-count">9</biblScope><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>Hoboken, USA</pubPlace><date type="published" when="2009-05">2009-05</date></imprint><idno type="ISSN">1939-5116</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1939-5116</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Airway</term><term>Airway epithelium</term><term>Allergic</term><term>Allergic asthma</term><term>Allergic rhinitis</term><term>Allergy clin immunol</term><term>Antibiotic</term><term>Asthma</term><term>Biol chem</term><term>Brosis</term><term>Cationic polymers</term><term>Cellular uptake</term><term>Chitosan</term><term>Chitosan nanospheres</term><term>Chloride ions</term><term>Control release</term><term>Current drug delivery approaches</term><term>Cystic</term><term>Drug deliv</term><term>Drug delivery</term><term>Epithelium</term><term>Gene</term><term>Gene delivery</term><term>Gene therapy</term><term>Gene transfer</term><term>Genet vaccines</term><term>High doses</term><term>Infection</term><term>Kumar</term><term>Lung function</term><term>Magnetic particles</term><term>Mild asthma</term><term>Mouse model</term><term>Nanobiotechnology nanomedicine</term><term>Nanomedicine</term><term>Nanoparticles</term><term>Nanoparticulate</term><term>Nanoparticulate delivery systems</term><term>Nanospheres</term><term>Nasal epithelium</term><term>Other hand</term><term>Polymer</term><term>Polymeric material</term><term>Promising approach</term><term>Pulmonary delivery</term><term>Respir</term><term>Respir crit care</term><term>Respiratory diseases</term><term>Respiratory infections</term><term>Respiratory syncytial virus infection</term><term>Side effects</term><term>Syncytial virus</term><term>Theophylline</term><term>Thiolated chitosan nanoparticles</term><term>Tissue engineering</term><term>Toxic effects</term><term>Tract infections</term><term>Transfection</term><term>Vaccine</term><term>Wires nanomedicine</term><term>World health organization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Treatment of respiratory diseases and infections has proved to be a challenging task, with the incidence of these ailments increasing worldwide. Nanotechnology‐based drug and gene delivery systems offer a possible solution to some of the shortfalls of the current treatment regimen. Nanobased drug delivery systems have revolutionised the field of pharmacotherapy by presenting the ability to alter the pharmacokinetics of the conventional drugs to extend the drug retention time, reduce the toxicity and increase the half‐life of the drugs. Delivery of exogenous genes to the airway epithelium in vivo has been limited by several physiological barriers, resulting in the low success rate of these systems. With the advent of nanotechnology, DNA compacted with cationic polymers to produce nanoparticles has exhibited a significant increase in the transfection efficiencies. With nanoparticulate drug/gene delivery systems, specific cells can be targeted by functionalising the polymeric nanoparticles with ligands that allow the particles to dock at a specific site of the cell. In addition, polymeric systems allow for the cargo to be released in a controlled and stimuli‐responsive manner. The advantages that nanoparticulate delivery systems present in the treatment of respiratory diseases and infections are summarised in this review. Copyright © 2009 John Wiley & Sons, Inc. For further resources related to this article, please visit the WIREs website.</div></front></TEI><affiliations><list><country><li>Afrique du Sud</li><li>États-Unis</li></country><region><li>Colorado</li></region></list><tree><country name="Afrique du Sud"><noRegion><name sortKey="Swai, Hulda" sort="Swai, Hulda" uniqKey="Swai H" first="Hulda" last="Swai">Hulda Swai</name></noRegion><name sortKey="Chelule, Paul" sort="Chelule, Paul" uniqKey="Chelule P" first="Paul" last="Chelule">Paul Chelule</name><name sortKey="Kalombo, Lonji" sort="Kalombo, Lonji" uniqKey="Kalombo L" first="Lonji" last="Kalombo">Lonji Kalombo</name><name sortKey="Semete, Boitumelo" sort="Semete, Boitumelo" uniqKey="Semete B" first="Boitumelo" last="Semete">Boitumelo Semete</name><name sortKey="Swai, Hulda" sort="Swai, Hulda" uniqKey="Swai H" first="Hulda" last="Swai">Hulda Swai</name><name sortKey="Swai, Hulda" sort="Swai, Hulda" uniqKey="Swai H" first="Hulda" last="Swai">Hulda Swai</name></country><country name="États-Unis"><region name="Colorado"><name sortKey="Kisich, Kevin" sort="Kisich, Kevin" uniqKey="Kisich K" first="Kevin" last="Kisich">Kevin Kisich</name></region><name sortKey="Sievers, Bob" sort="Sievers, Bob" uniqKey="Sievers B" first="Bob" last="Sievers">Bob Sievers</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001847 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001847 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4644A806C6CEE0618457F71979419A298BD69F69
|texte= Nanomedicine for respiratory diseases
}}
| This area was generated with Dilib version V0.6.33. |  |